Charles Schwab Investment Management Inc. Acquires 37,714 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Charles Schwab Investment Management Inc. raised its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 4.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 827,545 shares of the company’s stock after purchasing an additional 37,714 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.81% of Intellia Therapeutics worth $17,006,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of NTLA. Blue Trust Inc. lifted its holdings in shares of Intellia Therapeutics by 1,664.3% during the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after acquiring an additional 1,398 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Intellia Therapeutics by 763.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after acquiring an additional 1,550 shares during the period. Eastern Bank bought a new stake in shares of Intellia Therapeutics during the 3rd quarter worth approximately $41,000. Values First Advisors Inc. bought a new stake in shares of Intellia Therapeutics during the 3rd quarter worth approximately $54,000. Finally, First Horizon Advisors Inc. lifted its holdings in shares of Intellia Therapeutics by 22.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after acquiring an additional 472 shares during the period. Institutional investors own 88.77% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on NTLA. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a report on Friday, November 8th. Oppenheimer lowered their price objective on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Monday, November 11th. Canaccord Genuity Group reiterated a “buy” rating and set a $90.00 price objective on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. William Blair reiterated a “neutral” rating and set a $14.00 price objective on shares of Intellia Therapeutics in a research report on Monday, November 18th. Finally, Citigroup lowered their price objective on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $54.94.

Insider Transactions at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the transaction, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at $893,698.12. This represents a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.20% of the stock is currently owned by corporate insiders.

Intellia Therapeutics Stock Up 7.8 %

NTLA opened at $14.72 on Friday. Intellia Therapeutics, Inc. has a twelve month low of $12.82 and a twelve month high of $34.87. The company has a fifty day moving average of $16.61 and a 200-day moving average of $20.98. The stock has a market cap of $1.50 billion, a PE ratio of -2.71 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. During the same quarter last year, the company earned ($1.38) earnings per share. The company’s quarterly revenue was down 24.1% compared to the same quarter last year. Sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -5.12 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.